Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer
Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease which has an unpredictable risk of progression to muscle-invasive bladder cancer (MIBC). The selection of patients who may benefit from early radical intervention is a challenge. To define the useful prognostic markers for progres...
Gespeichert in:
| Veröffentlicht in: | Annals of diagnostic pathology 2019-04, Vol.39, p.42-52 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 52 |
|---|---|
| container_issue | |
| container_start_page | 42 |
| container_title | Annals of diagnostic pathology |
| container_volume | 39 |
| creator | Abdelrahman, Aziza E. Rashed, Hayam E. Elkady, Ehab Elsebai, Eman A. El-Azony, Ahmed Matar, Ihab |
| description | Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease which has an unpredictable risk of progression to muscle-invasive bladder cancer (MIBC). The selection of patients who may benefit from early radical intervention is a challenge. To define the useful prognostic markers for progression, we analyzed the immunohistochemical expression of fatty acid synthase (FASN), Her2/neu, and E2F1 in 60 cases of NMIBC who underwent TURBT and adjuvant intravesical bacillus-Calmette-Guérin (BCG). Their predicting role for tumor recurrence, progression, recurrence-free survival (RFS) and progression-free survival (PFS) was analyzed. High FASN expression was observed in 56.7% (34/60) of NMIBC cases, and FASN expression was significantly associated with the tumor size, grade, and tumor stage (p = 0.003, p |
| doi_str_mv | 10.1016/j.anndiagpath.2019.01.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179406849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1092913418303678</els_id><sourcerecordid>2179406849</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-2a7cc69281b6f545bcac836030b7393378e2654f8d8e4bafc7fb2f036a70c7713</originalsourceid><addsrcrecordid>eNqNkE1v1DAQhiMEol_8BWRuHJrUX4ntI1p1aaVKXOBsTexJ6yXrLHay0v57vN0WcexpPvTOvDNPVX1htGGUdTebBmL0AR53MD81nDLTUNZQyt9V56wVvNbM6Pclp4bXhgl5Vl3kvKGUMdmqj9WZoJ2WWnbnVVrDPB8IuOBJPsT5CTJekztM_Cbick0genLL14xAJrs0PcYpz8GRLaTfmDKZhuduwpzDFEmIJE6x3i7ZjViqPeSwR9KP4D0m4iA6TFfVhwHGjJ9e4mX1a337c3VXP_z4fr_69lA7KcVcc1DOdYZr1ndDK9vegdOio4L2ShghlEbetXLQXqPsYXBq6PlARQeKOqWYuKy-nvaWC_8smGe7DdnhOELEacmWM2XkEYQpUnOSujTlnHCwuxTKjwfLqD0itxv7H3J7RG4pswV5mf38YrP0W_T_Jl8ZF8HqJMDy7D5gstkFLCR8SOhm66fwBpu_77WYhw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2179406849</pqid></control><display><type>article</type><title>Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer</title><source>Elsevier ScienceDirect Journals</source><creator>Abdelrahman, Aziza E. ; Rashed, Hayam E. ; Elkady, Ehab ; Elsebai, Eman A. ; El-Azony, Ahmed ; Matar, Ihab</creator><creatorcontrib>Abdelrahman, Aziza E. ; Rashed, Hayam E. ; Elkady, Ehab ; Elsebai, Eman A. ; El-Azony, Ahmed ; Matar, Ihab</creatorcontrib><description>Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease which has an unpredictable risk of progression to muscle-invasive bladder cancer (MIBC). The selection of patients who may benefit from early radical intervention is a challenge. To define the useful prognostic markers for progression, we analyzed the immunohistochemical expression of fatty acid synthase (FASN), Her2/neu, and E2F1 in 60 cases of NMIBC who underwent TURBT and adjuvant intravesical bacillus-Calmette-Guérin (BCG). Their predicting role for tumor recurrence, progression, recurrence-free survival (RFS) and progression-free survival (PFS) was analyzed. High FASN expression was observed in 56.7% (34/60) of NMIBC cases, and FASN expression was significantly associated with the tumor size, grade, and tumor stage (p = 0.003, p < 0.001, p < 0.0001 respectively). Positive Her2/neu was noted in 18.3% (11/60) of the cases, and its expression was significantly associated with the tumor size, histologic grade, and tumor stage (p = 0.001, p = 0.002, p = 0.011 respectively). High E2F1 expression was detected in 40% of the cases, and it was associated with tumor size, histologic grade, and tumor stage (p < 0.001 for each). Analysis of follow-up period revealed that NMIBC with high FASN, positive Her2/neu, and high E2F1 expression exhibited a potent relation with tumor progression, shorter RFS, and poor PFS. Conclusions: High FASN, Her2/neu, and E2F1 are considered as adverse prognostic factors of tumor recurrence and progression in NMIBC and these patients should be followed carefully. Therefore, we suggest that FASN, Her2/neu, and E2F1 should be considered and evaluated during the selection of the appropriate management strategy for NMIBC patients.
•High FASN, Her2/neu and E2F1 are potent predictors of tumor progression in NMIBC.•High FASN, Her2/neu and E2F1 are associated with shorter PFS.•High FASN and E2F1 are associated with poor RFS.</description><identifier>ISSN: 1092-9134</identifier><identifier>EISSN: 1532-8198</identifier><identifier>DOI: 10.1016/j.anndiagpath.2019.01.002</identifier><identifier>PMID: 30684846</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>E2F1 ; FASN ; Her2/neu ; Immunohistochemistry ; Non-muscle-invasive bladder cancer ; Prognostic markers</subject><ispartof>Annals of diagnostic pathology, 2019-04, Vol.39, p.42-52</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-2a7cc69281b6f545bcac836030b7393378e2654f8d8e4bafc7fb2f036a70c7713</citedby><cites>FETCH-LOGICAL-c443t-2a7cc69281b6f545bcac836030b7393378e2654f8d8e4bafc7fb2f036a70c7713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1092913418303678$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30684846$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdelrahman, Aziza E.</creatorcontrib><creatorcontrib>Rashed, Hayam E.</creatorcontrib><creatorcontrib>Elkady, Ehab</creatorcontrib><creatorcontrib>Elsebai, Eman A.</creatorcontrib><creatorcontrib>El-Azony, Ahmed</creatorcontrib><creatorcontrib>Matar, Ihab</creatorcontrib><title>Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer</title><title>Annals of diagnostic pathology</title><addtitle>Ann Diagn Pathol</addtitle><description>Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease which has an unpredictable risk of progression to muscle-invasive bladder cancer (MIBC). The selection of patients who may benefit from early radical intervention is a challenge. To define the useful prognostic markers for progression, we analyzed the immunohistochemical expression of fatty acid synthase (FASN), Her2/neu, and E2F1 in 60 cases of NMIBC who underwent TURBT and adjuvant intravesical bacillus-Calmette-Guérin (BCG). Their predicting role for tumor recurrence, progression, recurrence-free survival (RFS) and progression-free survival (PFS) was analyzed. High FASN expression was observed in 56.7% (34/60) of NMIBC cases, and FASN expression was significantly associated with the tumor size, grade, and tumor stage (p = 0.003, p < 0.001, p < 0.0001 respectively). Positive Her2/neu was noted in 18.3% (11/60) of the cases, and its expression was significantly associated with the tumor size, histologic grade, and tumor stage (p = 0.001, p = 0.002, p = 0.011 respectively). High E2F1 expression was detected in 40% of the cases, and it was associated with tumor size, histologic grade, and tumor stage (p < 0.001 for each). Analysis of follow-up period revealed that NMIBC with high FASN, positive Her2/neu, and high E2F1 expression exhibited a potent relation with tumor progression, shorter RFS, and poor PFS. Conclusions: High FASN, Her2/neu, and E2F1 are considered as adverse prognostic factors of tumor recurrence and progression in NMIBC and these patients should be followed carefully. Therefore, we suggest that FASN, Her2/neu, and E2F1 should be considered and evaluated during the selection of the appropriate management strategy for NMIBC patients.
•High FASN, Her2/neu and E2F1 are potent predictors of tumor progression in NMIBC.•High FASN, Her2/neu and E2F1 are associated with shorter PFS.•High FASN and E2F1 are associated with poor RFS.</description><subject>E2F1</subject><subject>FASN</subject><subject>Her2/neu</subject><subject>Immunohistochemistry</subject><subject>Non-muscle-invasive bladder cancer</subject><subject>Prognostic markers</subject><issn>1092-9134</issn><issn>1532-8198</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkE1v1DAQhiMEol_8BWRuHJrUX4ntI1p1aaVKXOBsTexJ6yXrLHay0v57vN0WcexpPvTOvDNPVX1htGGUdTebBmL0AR53MD81nDLTUNZQyt9V56wVvNbM6Pclp4bXhgl5Vl3kvKGUMdmqj9WZoJ2WWnbnVVrDPB8IuOBJPsT5CTJekztM_Cbick0genLL14xAJrs0PcYpz8GRLaTfmDKZhuduwpzDFEmIJE6x3i7ZjViqPeSwR9KP4D0m4iA6TFfVhwHGjJ9e4mX1a337c3VXP_z4fr_69lA7KcVcc1DOdYZr1ndDK9vegdOio4L2ShghlEbetXLQXqPsYXBq6PlARQeKOqWYuKy-nvaWC_8smGe7DdnhOELEacmWM2XkEYQpUnOSujTlnHCwuxTKjwfLqD0itxv7H3J7RG4pswV5mf38YrP0W_T_Jl8ZF8HqJMDy7D5gstkFLCR8SOhm66fwBpu_77WYhw</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Abdelrahman, Aziza E.</creator><creator>Rashed, Hayam E.</creator><creator>Elkady, Ehab</creator><creator>Elsebai, Eman A.</creator><creator>El-Azony, Ahmed</creator><creator>Matar, Ihab</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201904</creationdate><title>Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer</title><author>Abdelrahman, Aziza E. ; Rashed, Hayam E. ; Elkady, Ehab ; Elsebai, Eman A. ; El-Azony, Ahmed ; Matar, Ihab</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-2a7cc69281b6f545bcac836030b7393378e2654f8d8e4bafc7fb2f036a70c7713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>E2F1</topic><topic>FASN</topic><topic>Her2/neu</topic><topic>Immunohistochemistry</topic><topic>Non-muscle-invasive bladder cancer</topic><topic>Prognostic markers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdelrahman, Aziza E.</creatorcontrib><creatorcontrib>Rashed, Hayam E.</creatorcontrib><creatorcontrib>Elkady, Ehab</creatorcontrib><creatorcontrib>Elsebai, Eman A.</creatorcontrib><creatorcontrib>El-Azony, Ahmed</creatorcontrib><creatorcontrib>Matar, Ihab</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of diagnostic pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdelrahman, Aziza E.</au><au>Rashed, Hayam E.</au><au>Elkady, Ehab</au><au>Elsebai, Eman A.</au><au>El-Azony, Ahmed</au><au>Matar, Ihab</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer</atitle><jtitle>Annals of diagnostic pathology</jtitle><addtitle>Ann Diagn Pathol</addtitle><date>2019-04</date><risdate>2019</risdate><volume>39</volume><spage>42</spage><epage>52</epage><pages>42-52</pages><issn>1092-9134</issn><eissn>1532-8198</eissn><abstract>Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease which has an unpredictable risk of progression to muscle-invasive bladder cancer (MIBC). The selection of patients who may benefit from early radical intervention is a challenge. To define the useful prognostic markers for progression, we analyzed the immunohistochemical expression of fatty acid synthase (FASN), Her2/neu, and E2F1 in 60 cases of NMIBC who underwent TURBT and adjuvant intravesical bacillus-Calmette-Guérin (BCG). Their predicting role for tumor recurrence, progression, recurrence-free survival (RFS) and progression-free survival (PFS) was analyzed. High FASN expression was observed in 56.7% (34/60) of NMIBC cases, and FASN expression was significantly associated with the tumor size, grade, and tumor stage (p = 0.003, p < 0.001, p < 0.0001 respectively). Positive Her2/neu was noted in 18.3% (11/60) of the cases, and its expression was significantly associated with the tumor size, histologic grade, and tumor stage (p = 0.001, p = 0.002, p = 0.011 respectively). High E2F1 expression was detected in 40% of the cases, and it was associated with tumor size, histologic grade, and tumor stage (p < 0.001 for each). Analysis of follow-up period revealed that NMIBC with high FASN, positive Her2/neu, and high E2F1 expression exhibited a potent relation with tumor progression, shorter RFS, and poor PFS. Conclusions: High FASN, Her2/neu, and E2F1 are considered as adverse prognostic factors of tumor recurrence and progression in NMIBC and these patients should be followed carefully. Therefore, we suggest that FASN, Her2/neu, and E2F1 should be considered and evaluated during the selection of the appropriate management strategy for NMIBC patients.
•High FASN, Her2/neu and E2F1 are potent predictors of tumor progression in NMIBC.•High FASN, Her2/neu and E2F1 are associated with shorter PFS.•High FASN and E2F1 are associated with poor RFS.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30684846</pmid><doi>10.1016/j.anndiagpath.2019.01.002</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1092-9134 |
| ispartof | Annals of diagnostic pathology, 2019-04, Vol.39, p.42-52 |
| issn | 1092-9134 1532-8198 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179406849 |
| source | Elsevier ScienceDirect Journals |
| subjects | E2F1 FASN Her2/neu Immunohistochemistry Non-muscle-invasive bladder cancer Prognostic markers |
| title | Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T18%3A56%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fatty%20acid%20synthase,%20Her2/neu,%20and%20E2F1%20as%20prognostic%20markers%20of%20progression%20in%20non-muscle%20invasive%20bladder%20cancer&rft.jtitle=Annals%20of%20diagnostic%20pathology&rft.au=Abdelrahman,%20Aziza%20E.&rft.date=2019-04&rft.volume=39&rft.spage=42&rft.epage=52&rft.pages=42-52&rft.issn=1092-9134&rft.eissn=1532-8198&rft_id=info:doi/10.1016/j.anndiagpath.2019.01.002&rft_dat=%3Cproquest_cross%3E2179406849%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2179406849&rft_id=info:pmid/30684846&rft_els_id=S1092913418303678&rfr_iscdi=true |